Vanguard Asset Management
UTHR icon

Vanguard Asset Management’s United Therapeutics UTHR Stock Holding History

Vanguard Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Sell
21,502
-1
-0% -$563 0.01% 673
2026
Q1 		$12.8M Buy
+21,503
New +$10.7M 0.01% 602

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Vanguard Asset Management's UTHR Position: Q2 2026 in Review

Vanguard Asset Management reduced its United Therapeutics (UTHR) stake by 0% in Q2 2026, selling an estimated $563 and leaving 21,502 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #673.

Vanguard Asset Management first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. The position peaked at $12.8M in Q1 2026. 818 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Vanguard Asset Management held 21,502 shares of United Therapeutics worth $11.7M as of Q2 2026.
  • Vanguard Asset Management sold 1 United Therapeutics share in Q2 2026, an estimated $563.
  • United Therapeutics made up 0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #673 holding.
  • Vanguard Asset Management first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Asset Management's United Therapeutics position peaked at $12.8M in Q1 2026.
  • 818 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.